Transanal endoscopic microsurgery with alternative neoadjuvant imatinib for localized rectal gastrointestinal stromal tumor: a single center experience with long-term surveillance.

Surgical endoscopy 2021 Vol.35(7) p. 3607-3617

Bai X, Zhou W, Li Y, Lin G

관련 도메인

Abstract

[BACKGROUND] Transanal endoscopic microsurgery (TEM) is widely used in the treatment of local rectal lesions and helps avoid radical surgery. This study evaluated the management and outcome in a long-term followed cohort of patients with localized rectal GIST underwent TEM with alternative neodajuvant imatinib (nIM).

[METHODS] A retrospective cohort study was undertaken of patients identified from a case database at Department of General Surgery, Peking Union Medical College Hospital (PUMCH) over a continuous period, from January 2006 to December 2017.

[RESULTS] Over 12 years, 42 patients presented with a primary rectal GIST in PUMCH. Median age was 49 (range 27-77) years. Neoadjuvant imatinib (nIM) therapy was used in 16 patients, significantly reducing mean tumor size from 4.41 to 2.46 cm (p < 0.001) and mitotic index (p = 0.041). All of these patients underwent TEM with no tumor rupture, nIM therapy enabled sphincter-preserving surgery to be undertaken in 16 (16/42) patients who would otherwise have required abdominoperineal resection or pelvic exenteration for tumor clearance and all patients (42/42) achieve R0 resection and negative margin. Imatinib was also used as postoperative adjuvant treatment in 15 patients with high-risk GIST. Median follow-up was 77 (range 14-144) and overall survival is 100%. In 42 patients, Local recurrence (LR) occurred in 3 of 42 patients and 1 of 42 patients developed distant metastasis (DM) in 112 months after TEM. In the univariate analysis, mitotic index (p = 0.028), NIH risk categories (p = 0.047) were predictive feature of local relapse.

[CONCLUSION] The application of nIM significantly decreased tumor size in large localized rectal GIST, which permitted TEM to preserve sphincter. The TEM procedure with alternative neoadjuvant imatinib therapy is a practicable treatment for patients with rectal GIST to preserve anus and have satisfied anal function.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 microsurgery 미세수술 dict 2
기법 endoscopic 내시경 dict 2
해부 NIH scispacy 1
합병증 rectal gastrointestinal stromal tumor scispacy 1
합병증 rectal lesions scispacy 1
합병증 pelvic scispacy 1
합병증 anus scispacy 1
합병증 anal scispacy 1
약물 imatinib C0935989
imatinib
scispacy 1
약물 [BACKGROUND] scispacy 1
질환 gastrointestinal stromal tumor C0238198
Gastrointestinal Stromal Tumors
scispacy 1
질환 tumor C0027651
Neoplasms
scispacy 1
질환 tumor rupture scispacy 1
질환 rectal GIST scispacy 1
질환 GIST scispacy 1
기타 patients scispacy 1

MeSH Terms

Adult; Aged; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Microsurgery; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Retrospective Studies; Transanal Endoscopic Microsurgery; Treatment Outcome

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문